Literature DB >> 23236064

No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques.

Dhanya K Williams1, Teresa A Galvin, Yamei Gao, Christina O'Neill, Dustin Glasner, Arifa S Khan.   

Abstract

The discovery of xenotropic murine leukemia virus-related virus (XMRV) in human tissue samples has been shown to be due to virus contamination with a recombinant murine retrovirus. However, due to the unknown pathogenicity of this novel retrovirus and its broad host range, including human cell lines, it is important to understand the modes of virus transmission and develop mitigation and management strategies to reduce the risk of human exposure and infection. XMRV transmission was evaluated by whole-blood transfusion in rhesus macaques. Monkeys were infected with XMRV to serve as donor monkeys for blood transfers at weeks 1, 2, and 3 into naïve animals. The donor and recipient monkeys were evaluated for XMRV infection by nested PCR assays with nucleotide sequence confirmation, Western blot assays for development of virus-specific antibodies, and coculture of monkey peripheral blood mononuclear cells (PBMCs) with a sensitive target cell line for virus isolation. XMRV infection was demonstrated in the virus-injected donor monkeys, but there was no evidence of virus transmission by whole-blood transfusion to naïve monkeys based upon PCR analysis of PBMCs using XMRV-specific gag and env primers, Western blot analysis of monkey plasma up to 31 to 32 weeks after transfusion, and coculture studies using monkey PBMCs from various times after transfusion. The study demonstrates the lack of XMRV transmission by whole-blood transfusion during the acute phase of infection. Furthermore, analysis of PBMC viral DNA showed extensive APOBEC-mediated G-to-A hypermutation in a donor animal at week 9, corroborating previous results using macaques and supporting the possible restriction of XMRV replication in humans by a similar mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23236064      PMCID: PMC3571456          DOI: 10.1128/JVI.02326-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Xenotropic murine leukemia virus-related virus (XMRV) and blood transfusion: report of the AABB interorganizational XMRV task force.

Authors:  Harvey G Klein; Roger Y Dodd; F Blaine Hollinger; Louis M Katz; Steven Kleinman; K Kimberly McCleary; Robert H Silverman; Susan L Stramer
Journal:  Transfusion       Date:  2011-01-14       Impact factor: 3.157

2.  The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans.

Authors:  Graham Simmons; Simone A Glynn; Jerry A Holmberg; John M Coffin; Indira K Hewlett; Shyh-Ching Lo; Judy A Mikovits; William M Switzer; Jeffrey M Linnen; Michael P Busch
Journal:  Transfusion       Date:  2011-03-01       Impact factor: 3.157

3.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

4.  Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV.

Authors:  Nattawat Onlamoon; Jaydip Das Gupta; Prachi Sharma; Kenneth Rogers; Suganthi Suppiah; Jeanne Rhea; Ross J Molinaro; Christina Gaughan; Beihua Dong; Eric A Klein; Xiaoxing Qiu; Sushil Devare; Gerald Schochetman; John Hackett; Robert H Silverman; François Villinger
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

5.  Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells.

Authors:  Chawaree Chaipan; Kari A Dilley; Tobias Paprotka; Krista A Delviks-Frankenberry; Narasimhan J Venkatachari; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

6.  An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV.

Authors:  Eiji Sato; Rika A Furuta; Takayuki Miyazawa
Journal:  Retrovirology       Date:  2010-12-20       Impact factor: 4.602

7.  Investigation into the presence of and serological response to XMRV in CFS patients.

Authors:  Otto Erlwein; Mark J Robinson; Steve Kaye; Gillian Wills; Shozo Izui; Simon Wessely; Jonathan Weber; Anthony Cleare; David Collier; Myra O McClure
Journal:  PLoS One       Date:  2011-03-09       Impact factor: 3.240

8.  PCR master mixes harbour murine DNA sequences. Caveat emptor!

Authors:  Philip W Tuke; Kate I Tettmar; Asif Tamuri; Jonathan P Stoye; Richard S Tedder
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

9.  Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences.

Authors:  Brendan Oakes; Albert K Tai; Oya Cingöz; Madeleine H Henefield; Susan Levine; John M Coffin; Brigitte T Huber
Journal:  Retrovirology       Date:  2010-12-20       Impact factor: 4.602

10.  DNA extraction columns contaminated with murine sequences.

Authors:  Otto Erlwein; Mark J Robinson; Simon Dustan; Jonathan Weber; Steve Kaye; Myra O McClure
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

View more
  2 in total

1.  Barriers to Infection of Human Cells by Feline Leukemia Virus: Insights into Resistance to Zoonosis.

Authors:  Anne Terry; Anna Kilbey; Asif Naseer; Laura S Levy; Shamim Ahmad; Ciorsdaidh Watts; Nancy Mackay; Ewan Cameron; Sam Wilson; James C Neil
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

2.  Evaluation of the broad-range PCR-electrospray ionization mass spectrometry (PCR/ESI-MS) system and virus microarrays for virus detection.

Authors:  Lanyn P Taliaferro; Teresa A Galvin; Hailun Ma; Syed Shaheduzzaman; Dhanya K Williams; Dustin R Glasner; Arifa S Khan
Journal:  Viruses       Date:  2014-04-25       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.